-
2023-505121-14-00
5
2024-01-18
Moderate to Severe Plaque Psoriasis
-
2022-503126-12-01
5
2024-01-05
Hypoparathyroidism
-
2023-506993-11-00
1
2023-11-23
Relapsed or refractory multiple myeloma
-
2024-511337-35-00
4
2023-11-16
The trial will include patients with so called "fusion-driven", metast
-
2023-504247-13-00
4
2023-10-17
Large cell neuroendocrine carcinoma
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2024-510635-21-00
5
2023-05-09
warm autoimmune haemolytic anaemia (wAIHA)
-
2022-500479-29-00
10
2023-03-28
International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2022-500367-12-00
5
2022-11-30
Dermatomyositis
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2022-500508-23-00
1
2022-10-28
Advanced solid tumors
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2022-503012-16-00
5
2022-07-20
Patients on treatment with Factor Xa Inhibitor needing for an urgent i
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2023-509248-86-00
10
2022-03-11
Moderately to Severely Active Ulcerative Colitis
-
2024-514617-35-00
4
2021-12-20
Progressive forms of Multiple Sclerosis
-
2023-509138-21-00
5
2021-08-26
Pulmonary Arterial Hypertension (PAH)
-
2024-516739-29-00
4
2019-01-23
Relapsing-remitting multiple sclerosis
-
2025-524580-21-00
10
2026-06-01
Grass pollen induced allergic rhinitis or rhinoconjunctivitis
-
2025-523975-48-00
5
2026-05-08
Obesity
-
2025-523552-31-00
5
2026-05-07
Systemic Lupus Erythematosus